The Edwards SAPIEN transcatheter heart valve significantly improves survival
“On the basis of a rate of death from any cause at 1 year that was 20 percentage points lower with TAVI than with standard therapy, balloon-expandable TAVI should be the new standard of care for patients with aortic stenosis who are not suitable candidates for surgery.”
–The PARTNER Trial Investigators1
Co-Primary endpoint: All-Cause mortality1
The Edwards SAPIEN transcatheter heart valve significantly improves patient symptoms and quality of life
The magnitude of improvement in quality of life scores with TAVI was roughly equivalent to a 10-year reduction in age.2
Kansas City Cardiomyopathy Questionnaire (KCCQ) scores over time2
Among inoperable patients with severe AS, TAVI conferred a 25-point improvement in the KCCQ quality of life score after one year.2
- Leon MB, Smith CR, Mack M, et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-607.
- Reynolds MR, Magnuson EA, Lei Y, et al.; Placement of Aortic Transcatheter Valves (PARTNER) Investigators. Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Circulation 2011;124:1964-72.
* Patients in control arm received best medical management which frequently (78.2%) included balloon aortic valvuloplasty
Any quotes used in this material are taken from independent third-party publications and are not intended to imply that such third party reviewed or endorsed any of the products of Edwards Lifesciences.